Investor Ideas #Potcasts: #Cannabis News and #Stocks on the Move (CSE:
$CNNA.C) (OTCQB: $GBLX) (TSX: $VFF.TO) (NASDAQ: $VFF) (OTC: $DXBRF) (CSE: $THC.C)
Delta, Kelowna, BC –June
11, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news
source covering leading sectors including marijuana and hemp stocks and its
potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and
experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/06111CNNA-GBLX-VFF-DXBRF-THC.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com “potcasts”,
looking at cannabis news, stocks to watch as well as insights from thought
leaders and experts.
We’re
back from New York and ready to look at a few early announcements.
If
you haven’t taken a listen yet, both out interviews from New York with Ryan Fishoff of American
Premium Water (OTC:HIPH) and Scott Greiper of Viridian
Capital Advisors are worth looking into.
Before
getting into announcements, The 22nd edition of The Sanofi Canada Healthcare Survey uncovered gaps in knowledge that can serve
to help guide decision-making among employers who provide health benefit plans
to employees. A persistent gap is employers' underestimation of the presence of
chronic disease in their workforce, which suggests they may also underestimate
the negative impact of unmanaged disease on productivity.
"Providers
of workplace health benefit plans can use these results to help drive new
benefit offerings and wellness initiatives that focus on supporting plan
members with chronic disease," says Michael Mullette, President and CEO of
Sanofi Canada. "The past few years have seen positive growth in supports
for mental health, which can serve as a model for other major chronic
conditions such as diabetes and cardiovascular disease."
The
Sanofi Canada Healthcare Survey also reveals employees' and employers' opinions
on numerous other timely topics, including precision medicine, targeted health
messaging, national Pharmacare and medical cannabis. The full report is
available from Sanofi Canada's website at
www.sanofi.ca/en/about-us/sanofi-canada-healthcare-survey.
Growing urgency to
do more for chronic disease
● 54% of plan members have been diagnosed
with at least one chronic disease or condition, increasing to 69% among those
aged 55 to 64.
● Plan sponsors estimate that 39% of their
workforce has a chronic condition.
● When chronic pain is added to the equation,
67% of employees have a condition that can impact productivity and lead to
repeated absences from the workplace.
● 87% of employees with a chronic condition
would like to know more about their condition and how to treat it.
● 82% of employers would like their benefit
plan to do more to support employees with chronic conditions.
Changing menu for
health benefits
● 74% of employees would consent to
pharmacogenetic testing so that physicians can prescribe medications that are
most likely to work well for them (referred to as precision medicine or
personalized medicine); 65% of employers are interested in providing coverage
for pharmacogenetic testing.
● 65% of employees would consent to receive
health information based on their personal use of benefits; 74% of employers
would like their benefit plan's insurance carrier to send such targeted health
messaging to employees.
● 45% of employers agree medical cannabis
should be covered by their workplace health benefit plan, up from 34% in 2018;
64% of employees believe medical cannabis should be covered.
Workplace drug
plans misunderstood
● Employees and employers significantly
underestimate the number of drugs covered by workplace drug plans, and
overestimate the number of drugs covered by provincial drug plans.
● 77% of employees and 52% of employers have
low or no knowledge about a possible national Pharmacare program in Canada.
● Levels of support are high among employees
(87%) and employers (84%) for a Pharmacare that fills gaps in coverage for
Canadians who have no insurance or are underinsured, and does not affect
workplace drug plans.
CannaOne
Technologies (CSE: CNNA) announced that it has easily garnered well in excess
of the initial 10,000 member sign-up target it had set for the BWell CBD Online
Marketplace 10 day pre-launch referral
campaign. The pre-launch campaign
adopted a referral based sign-up initiative to ensure the marketplace would
possess the foundation of a truly authentic community of highly engaged
customers. There was no better way to make certain those are the types of
members registering for the marketplace, that to work from the premise that the
most powerful and effective way to introduce a new company to a diverse
clientele was by way of a credible referral. The referral campaign will remain
an on-going business strategy and sign-ups are expected to continue to grow
exponentially. The BWell CBD Online
Marketplace will be launching later this month with a significant customer base
eager to purchase the plethora of premium CBD products to be offered.
Stated
Solomon Riby Williams, CEO: "We saw the pre-launch undertaking as a way to
not only make people feel special, but at the same time to educate them to the
advantages and benefits of the BWell marketplace. Education is everything in
this industry and we exert a lot of effort towards assisting our new customers
to make well-informed buying decisions, that render the best solutions for
their own individual needs. We also understand how important it is for
customers to be introduced to BWell through a referral from someone they know;
a friend, or a family member or even by digital word of mouth. Our goal was to
make sure to garner and build a solid community of membership in advance of the
marketplace being officially open for business, and with that goal in mind, we
are ecstatic that the reception for membership to the pre-launch has surpassed
all our expectations as we have already outdone our target of 10,000 sign-ups
for the launch of BWell later this month".
GB Sciences, Inc. (OTCQB:GBLX) today announced it has obtained an exclusive license to
formulate, manufacture, and sell cannabis-infused oral thin films through its
MME-licensed subsidiaries and affiliates GB Sciences Louisiana, LLC, GB
Sciences Nevada, LLC, and GB Sciences Las Vegas, LLC, under US Patent Number
10,265,362 B2 issued April 2019.
GB
Sciences' new oral thin films will be sold in Louisiana and Nevada, reflecting
the company's commitment to providing advanced medical cannabis products. Oral
thin films are rapidly gaining popularity due to their efficacy, convenience,
and discreteness, and sales are increasing rapidly in major cannabis markets
including California and Colorado.
"Securing
this patented technology will allow us to get our patent-pending active
pharmaceutical ingredients into the hands of patients in Louisiana and Nevada
right away. This is great for patients, who have access to an entirely new way
to consume precisely-dosed cannabis without the potential drawbacks of other
delivery systems. And nobody else has this technology - making it a good
mechanism for GB Sciences to further monetize its considerable intellectual
property portfolio," explained John Poss, CEO and Chairman of GB Sciences,
Inc.
"Oral
thin films are very effective, easy to use, and have many advantages over other
delivery systems on the market. We can precisely dose each strip, and patients
who can't swallow will have no problem taking these," said Dr. Andrea
Small-Howard, Chief Science Officer and Director of GB Sciences. "The
active ingredients in cannabis, such as cannabinoids and terpenes, are more
bioavailable via oral thin films because they're absorbed directly by the cells
in the mouth, then pass into the bloodstream. That means quicker delivery and
more complete dosing, without some of the negatives associated with
edibles."
Village Farms
International, Inc. (TSX: VFF) (NASDAQ: VFF) today announced that Governor Greg Abbott has signed into
law Texas House Bill 1325 (the "Texas Hemp Legislation"), which
effectively legalizes the cultivation of hemp and processing of hemp and
hemp-derived products, including cannabidiol (CBD) in the State.
As
previously announced, in anticipation of the passage of the hemp legislation in
Texas, Village Farms has begun conversion of half of its 1.3 million square
foot, ultra-high-tech Permian Basin greenhouse (which utilizes the Company's
proprietary GATES® technology) for
cultivation of high-CBD hemp and CBD extraction. The Texas Hemp Legislation will require
licenses for both the cultivation and processing of hemp and Village Farms
plans to apply for the requisite licenses as soon as it is permitted to do
so. No time frame has yet been provided
by the State of Texas for the licensing process.
"The
Governor's signing of this bill into law formalizes a significant opportunity
for Village Farms as a first mover in the Texas hemp industry and will allow us
to capitalize on the expected demand for premium-grade hemp grown in
controlled-environment facilities for the high-end health and wellness and the
pharmaceutical industries," said Michael DeGiglio, CEO, Village Farms
International. "Conversion of half of Permian Basin greenhouse in West
Texas for hemp production is now well underway and we look forward to
commencing production as soon as possible upon Texas establishing a licensing
and regulatory framework for hemp and CBD."
Dixie Brands Inc. (CSE: DIXI.U), (OTC: DXBRF) today announced that it is entering the Oklahoma
medical-use cannabis market through a manufacturing, distribution and licensing
agreement the Company has signed with Globus Holdings ("Globus").
Oklahoma will become the sixth state in Dixie's growing U.S. footprint.
Pursuant
to the agreements, Dixie will work in conjunction with Globus to use Dixie's
intellectual property, including its proprietary formulations and preparation
methods as well as the associated trademarks, in the State of Oklahoma. Globus'
manufacturing facility in Tulsa will make use of Dixie's proprietary
formulations and proven "GMP" (good manufacturing practices) and
quality control procedures. Initial products including gummies, mints, pills,
vaporizers, and drinks are expected to be available beginning in the Fall of
this year.
"We
continue to execute on our stated priorities for 2019, and expanding into new
U.S. states is at the top of that list," said Chuck Smith, President and
CEO, Dixie Brands. "We are very excited to introduce Dixie products to
Oklahoma. The state has embraced legal cannabis over the past year and we
anticipate that our relatively early entry into the market will help establish
Dixie as one of the top-selling brands."
Oklahoma
has proceeded quickly to license medical marijuana patients and industry
participants since voters approved medical use through a June 2018 ballot
question.
According
to the Oklahoma Medical Marijuana Authority, the state has approved 129,000
patients, as well as growers, processors and nearly 1,500 dispensaries. Based
on recent reports from the Oklahoma Tax Commission, cannabis sales in Oklahoma
exceeded $23 million in May 2019, and have been growing significantly from
month to month as industry participants continue to ramp their operations.
THC
BioMed Intl Ltd. (CSE: THC) announced that it is the first Canadian Licensed
Producer to automate the pre-rolling of cigarettes containing 100% cannabis (the
"Pure Cannabis Cigarettes"). In the same way automation changed the
tobacco industry, THC BioMed is confident the automation of Pure Cannabis
Cigarettes will bring meaningful changes to the current cannabis industry and
its bottom line.
Pure
Cannabis Cigarettes to be Introduced to Canadian Cannabis Market (CNW Group/THC
BioMed)
The automated cigarette manufacturing plant
has been installed at THC BioMed's flagship Acland Road location. THC will begin the production and sales of
commercial-grade Pure Cannabis Cigarettes, a first in Canada.
The Pure Cannabis Cigarettes are to be
packaged in lots of 3 and 20. Each Pure Cannabis Cigarette will be intended for
a single-use session and will come with a commercial-grade cigarette filter.
There will be no tobacco in the Pure Cannabis Cigarettes.
"We are very pleased to offer
Canadians a better way of smoking cannabis, as we monitored an increase in
demand for our best-selling pre-rolls, we acknowledged that it was our duty to
ensure we distribute the best products possible. We are pleased to be the first
cannabis producer to put filters between the cannabis we are selling, and our
consumers. Filters were invented to protect the consumer and not degrade the
experience. "We promise our Pure Cannabis Cigarettes will offer the same
potency as our regular best-selling pre-rolls. I am predicting consumers will
gravitate towards this finished type of product and the old way of rolling joints
will be something of the past," said John Miller, President and CEO of THC
BioMed.
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also
available on iTunes, Spotify, Google
Play Music, Stitcher, Spreaker, YouTube
via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. Disclosure: the HIPH podcast mentioned was a paid for
service on Investorideas
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use
of cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
